A Phase 3 Study of Eltrombopag vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

K
Kerry Hege, MD

Primary Investigator

Overview

The purpose of this study is to determine if Eltrombopag is as effective of a treatment for patients with newly diagnosed Immune Thrombocytopenia (ITP) when compared to standard treatment.

Description

Participants will not be paid for their participation.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Immune Thrombocytopenia
  • Age: Between 1 Years - 17 Years
  • Gender: All

Inclusion Criteria
Newly diagnosed ITP (<3 months from diagnosis (first abnormal platelet count)
Requires pharmacologic treatment from the perspective of the treating clinician.

Updated on 25 Mar 2024. Study ID: 1905858882 (PHO-BAYLOR-ICON3)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center